Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques

• Published in: bioRxiv
• Main Authors: Huang, Lulu, Zhao, Tongyi, Zhao, Weijun, Shao, Andong, Zhao, Huajun, Ma, Wenxuan, Gong, Yingfei, Zeng, Xianhuan, Weng, Changzhen, Bu, Lingling, Di, Zhenhua, Sun, Shiyu, Dai, Qinsheng, Sun, Minhui, Wang, Limei, Liu, Zhenguang, Shi, Leilei, Hu, Jiesen, Fang, Shentong, Zhang, Cheng, Zhang, Jian, Wang, Guan, Lore, Karin, Yang, Yong, Ang, Lin
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 22.01.2024
• Subjects: Antigen presentation; Antigen processing; Correlation analysis; Glycoprotein E; Herpes viruses; Herpes zoster; Immunity; Immunogenicity; Licenses; Lipids; Lymphocytes T; mRNA vaccines; Nanoparticles; Public health; Transcriptomics; Vaccine development; Varicella
• DOI: 10.1101/2023.08.16.553640

Herpes zoster remains an important global health issue and mainly occurs in aged and immunocompromised individuals with an early exposure history to Varicella Zoster Virus (VZV). Although the licensed vaccine Shingrix has a remarkably high efficacy, undesired reactogenicity and increasing global demand causing vaccine shortage urged the development of improved or novel VZV vaccines. In this study, we developed a novel VZV mRNA vaccine candidate (named as ZOSAL) containing sequence-optimized mRNAs encoding full-length glycoprotein E encapsulated in an ionizable lipid nanoparticle. In mice and rhesus macaques, ZOSAL demonstrated superior immunogenicity and safety in multiple aspects over Shingrix, especially in the induction of strong T cell immunity. Transcriptomic analysis revealed that both ZOSAL and Shingrix could robustly activate innate immune compartments, especially Type-I IFN signaling and antigen processing/presentation. Multivariate correlation analysis further identified several early factors of innate compartments that can predict the magnitude of T cell responses, which further increased our understanding of the mode of action of two different VZV vaccine modalities. Collectively, our data demonstrated the superiority of VZV mRNA vaccine over licensed subunit vaccine. The mRNA platform therefore holds prospects for further investigations in next-generation VZV vaccine development.Competing Interest StatementJ.H. is an employee of Firestone Biotechnologies, which focuses on the development of novel ionizable lipids and LNP formulation. Firestone has filed a patent on the novel ionizable lipid (YX-02) used in this study. All other authors declare no conflict of interest.Footnotes* We have updated some of the figures in this revised version.